Mark R. Hake

Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Wait Until Naked Brand Falls to 34 Cents Before Even Thinking About Buying

By Mark R. Hake, CFA

Naked has a cash war chest and a small online business worth $305 million in total, or 34 cents per share. Here's what to do with NAKD stock.

Wells Fargo Stock Can Rise 22% if the Dividend Keeps Increasing

By Mark R. Hake, CFA

Wells Fargo looks too cheap right now. WFC stock is worth at least $60 given new growth in earnings, tangible book value and dividends.

DraftKings’ Q2 Earnings Show the Stock May Be Worth $80-Plus

By Mark R. Hake, CFA

DraftKings' Q2 sales and earnings surprise analysts, pushing up its inherent value. DKNG stock could be worth 56% more at $80.93, assuming it achieves 2025 revenue and margin targets.

Senseonics Could Go Higher, Especially if It Nabs FDA Approval

By Mark R. Hake, CFA

Senseonics looks interesting here, especially with possible FDA approval. SENS stock is worth about 24% more at over $4, or even $6-plus once its CGM rolls out.

The Delta Variant Is a Shot in the Arm for Vaxart’s Pill Vaccine

By Mark R. Hake, CFA

The Delta Covid variant gives Vaxart new life with its oral vaccine and could boost VRXT stock. VXRT stock is worth over 30% more at $13.00 if its Covid pill works, according to sell-side analysts.

Load More